Back to top
more

INmune Bio (INMB)

(Delayed Data from NSDQ)

$11.84 USD

11.84
439,958

+0.07 (0.59%)

Updated Apr 30, 2024 04:00 PM ET

After-Market: $11.84 0.00 (0.00%) 7:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Wall Street Analysts Predict a 99% Upside in INmune Bio, Inc. (INMB): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for INmune Bio, Inc. (INMB) points to a 98.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Can INmune Bio, Inc. (INMB) Climb 105% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 104.7% upside potential for INmune Bio, Inc. (INMB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Shrabana Mukherjee headshot

New Analysts Initiate Coverage: 5 Stocks for Higher Returns

by Shrabana Mukherjee

Increased analyst coverage over the past few weeks may lead to solid price appreciation for stocks like Malibu (MBUU), Cantaloupe (CTLP), INmune (INMB), Swedish Match (SWMAY) and GATX.

INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study

by Zacks Equity Research

The FDA places clinical hold on INmune Bio's (INMB) IND application to begin a phase II study on the investigational TNF inhibitor, XPro1595, for Alzheimer's disease.

Biotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers Updates

by Zacks Equity Research

Regulatory updates and acquisition news from Entasis (ETTX) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.

INmune (INMB) Begins Dosing in Mid-Stage Study With AD Candidate

by Zacks Equity Research

INmune (INMB) doses the first patient in a phase II study with its investigational TNF inhibitor to treat Alzheimer's disease. Stock rises more than 12% post this announcement.

Biogen (BIIB) Seeks Approval for Another Alzheimer's Candidate

by Zacks Equity Research

Biogen (BIIB) and partner Eisai start rolling submission of a regulatory filing seeking approval for lecanemab (BAN2401) as a potential approval for early Alzheimer's disease.

Biotech Stock Roundup: MRNA Submits Vaccine Data, BMRN Down on Clinical Hold & More

by Zacks Equity Research

Regulatory and pipeline updates from Moderna (MRNA) and BioMarin (BMRN), among others, have been in focus in the biotech industry over the past week.

INmune (INMB) Announces Positive Data for its AD Candidate

by Zacks Equity Research

INmune Bio (INMB) announces positive data for its AD candidate, XPro, from an early stage study. Shares are up in pre-market.

Kinjel Shah headshot

6 Small Drug Stocks in Focus Ahead of World Alzheimer's Day

by Kinjel Shah

Here we discuss six small-cap companies with promising candidates in their pipeline for Alzheimer's disease.